Therapeutic utility of phosphodiesterase type I inhibitors in neurological conditions

Frontiers in Neuroscience

Volumn , Issue FEB, 2011, Pages

  Medina, Alexandre E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alzheimer; cAMP; cGMP; Drug development; Fetal alcohol spectrum disorders; Parkinson; Phosphodiesterase; Vinpocetine

Indexed keywords

AMANTADINE; CAFFEINE; NIMODIPINE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE TYPE I INHIBITOR; SELEGILINE; UNCLASSIFIED DRUG; VINPOCETINE; ZAPRINAST;

ALZHEIMER DISEASE; BRAIN ISCHEMIA; COGNITIVE DEFECT; DEMENTIA; DRUG EFFECT; DRUG MECHANISM; DRUG SPECIFICITY; ENZYME ACTIVITY; ENZYME INHIBITION; FETAL ALCOHOL SYNDROME; HUMAN; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; REVIEW;

EID: 84861141042     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2011.00021     Document Type: Review

References (78)

1. Atkins, C. M., Selcher, J. C., Petraitis, J. J., Trzaskos, J. M., and Sweatt, J. D. (1998). The MAPK cascade is required for mammalian associative learning. Nat. Neurosci. 1, 602-609.
2. Bagetta, V., Ghiglieri, V., Sgobio, C., Calabresi, P., and Picconi, B. (2010). Synaptic dysfunction in Parkinson's disease. Biochem. Soc. Trans. 38, 493-497.
3. Barco, A., Alaarcon, J. M., and Kandel, E. (2002). Expression of constitutively active CREB protein facilitates the late phase of long-term potentiation by enhancing synaptic capture. Cell 35, 345-353.
4. Beavo, J. A. (1995). Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75, 725-748.
5. Bereczki, D., and Fekete, I. (2009). Vinpocetine for acute ischaemic stroke. Cochrane Database Syst. Rev. 23, CD000480.
6. Blaha, L., Erzigkeit, H., Adamczyk, A., Freytag, S., and Schaltenbrand, R. (1989). Clinical evidence of the effectiveness of vinpocetine in the treatment of organic psychosyndrome. Hum. Psychopharmacol. 4, 103-111.
7. Bourtchouladze, R., Lidge, R., Catapano, R., Stanley, J., Gossweiler, S., Romashko, D., Scott, R., and Tully, T. (2003). A mouse model of Rubinstein- Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. Proc. Natl. Acad. Sci. U.S.A. 100, 10518-10522.
8. Brostom, C. O., Huang, Y. C., Breckenridge, B., and Wolff, D. J. (1975). Identification of a calcium-binding protein as a calcium-dependent regulatory of brain adenylate cyclase. Proc. Natl. Acad. Sci. U.S.A. 73, 64-68.
9. Chen, J. J., and Swope, D. M. (2007). Pharmacotherapy for Parkinson's disease. Pharmacotherapy 27, 161s-173s.
10. Chen, R. W., Williams, A. J., Liao, Z., Yao, C., Tortella, F. C., and Dave, J. R. (2007). Broad spectrum neuroprotection profile of phosphodiesterase inhibitors as related to modulation of cell-cycle elements and caspase-3 activation. Neurosci. Lett. 418, 165-169.
11. Cunha, R. A., and Agostinho, P. M. (2010). Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline. J. Alzheimers Dis. 20, S95-S116.
12. DeNoble, V. J. (1987). Vinpocetine enhances retrieval of a step-through passive avoidance response in rats. Pharmacol. Biochem. Behav. 26, 183-186.
13. Deshmukh, R., Sharma, V., Mehan, S., Sharma, N., and Bedi, K. L. (2009). Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine - a PDE1 inhibitor. Eur. J. Pharmacol. 620, 49-56.
14. Dyke, H. J., and Montana, J. G. (1999). The therapeutic potential of PDE4 inhibitors. Expert Opin. Investig. Drugs 8, 1301-1325.
15. Etkin, A., Alarcon, J. M., Weisberg, S. P., Touzani, K., Huang, Y. Y., Nordheim, A., and Kandel, E. R. (2006). A role in learning for SRF: deletion in the adult forebrain disrupts LTD and the formation of an immediate memory of a novel context. Neuron 50, 127-143.
16. Fenzl, E., Apecechea, M., Schaltenbrand, R., and Friedel, R. (1986). " Long-term study concerning tolerance and efficacy of vinpocetine in elderly patients suffering from a mild to moderate organic psychosyndrome," in Senile Dementias: Early Detection, eds A. Bes, J. Cahn, R. Cahn, S. Hoyer, J. P. Marc-Vergnes, and H. M. Wisniewski (London: John Libby Eurotext), 580-585.
17. Ferguson, G. D., and Storm, D. R. (2004). Why calcium-stimulated adenylyl cyclases? Physiology 19, 271-276.
18. Filgueiras, C. C., Krahe, T. E., and Medina, A. E. (2010). Phosphodiesterase type 1 inhibition improves learning in rats exposed to alcohol during the third trimester equivalent of human gestation. Neurosci. Lett. 473, 202-207.
19. Frank, D. A., and Greenberg, M. E. (1994). CREB: a mediator of long-term memory from mollusks to mammals. Cell 79, 5-8.
20. Fredholm, B. B., Battig, K., Holmen, J., Nehlig, A., and Zvartau, E. E. (1999). Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 51, 83-133.
21. Giorgi, M., D'Angelo, V., Esposito, Z., Nuccetelli, V., Sorge, R., Martorana, A., Stefani, A., Berardi, G., and Sancesario, G. (2008). Lowered cAMP and cGMP signalling in the brain during levedopa-induced dyskinesias in hemiParkinsonian rats: new aspects in the pathogenic mechanisms. Eur. J. Neurosci. 28, 941-950.
22. Glazewski, S., Barth, A. L., Wallace, H., McKenna, M., Silva, A., and Fox, K. (1999). Impaired experience-dependent plasticity in barrel cortex of mice lacking the alpha and delta isoforms of CREB. Cereb. Cortex 9, 249-256.
23. Goraya, T. E., and Cooper, D. M. (2005). Ca2+-calmodulin-dependent phosphodiesterase (PDE1): current perspectives. Cell. Signal. 17, 789-797.
24. Hindmarch, I., Fuchs, H. H., and Erzigkeit, H. (1991). Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int. Clin. Psychopharmacol. 6, 31-43.
25. Jeon, K.-I., Xu, X., Aizawa, T., Lim, J. H., Jono, H., Kwon, D.-S., Abe, J.-I., Berk, B., Li, J.-D., and Yan, C. (2010). Vinpocetine inhibits NF-kBdependent inflammation via an IKKdependent but PDE-independent mechanism. Proc. Natl. Acad. Sci. U.S.A. 107, 9795-9800.
26. Josselyn, S. A., and Nguyen, P. V. (2005). CREB, synapses and memory disorders: past progress and future challenges. Curr. Drug. Targets CNS Neurol. Disord. 4, 481-497.
27. Kakkar, R., Raju, R. V. S., Rajput, A., and Sharma, R. K. (1996). Inhibition of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes by deprenyl. Life Sci. 59, 337-341.
28. Kakkar, R., Raju, R. V. S., Rajput, A., and Sharma, R. K. (1997). Amantadine: an antiParkinsonian agent inhibits bovine 60 kDa calmodulin-dependent cyclic nucleotide phosphodiesterase isozyme. Brain Res. 749, 294.
29. Kakkar, R., Raju, R. V. S., and Sharma, R. K. (1999). Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1). Cell. Mol. Life Sci. 55, 1164-1186.
30. Kitagawa, K. (2007). CREB and cAMP response element-mediated gene expression in the ischemic brain. FEBS Lett. 274, 3210-3217.
31. Krahe, T. E., Wang, W., and Medina, A. E. (2008). Vinpocetine increase phosphorylation of CREB and restores orientation selectivity in a ferret model of fetal alcohol spectrum disorder. Int. J. Dev. Neurosci. 26, 890.
32. Krahe, T. E., Wang, W., and Medina, A. E. (2009). Phosphodiesterase inhibition increases CREB phosphorylation and restores orientation selectivity in a model of fetal alcohol spectrum disorders. PLoS ONE 4, e6643. doi: 10.1371/ journal.pone.0006643
33. Lakics, V., Karran, E. H., and Boess, F. G. (2010). Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 59, 367-374.
34. Lamprecht, R. (2005). CREB: a message to remember. Cell. Mol. Life Sci. 55, 554-563.
35. Lavaur, J., Bernard, F., Trifilieff, P., Pascoli, V., Kappes, V., Pages, C., Vanhoutte, P., and Caboche, J. (2008). A TAT-DEFElk-1 peptide regulates the cytonuclear trafficking of Elk-1 and controls cytoskeleton dynamics. J. Neurosci. 27, 14448-14458.
36. Lendvai, B., Zelles, T., Rozsa, B., and Vizi, E. S. (2003). A vinca alkaloid enhances morphological dynamics of dendritic spines of neocortical layer 2/3 pyramidal cells. Brain Res. Bull. 59, 257-260.
37. Lonze, B. E., and Ginty, D. D. (2002). Function and regulation of CREB family transcription factors in the nervous system. Neuron 35, 605-623.
38. Malenka, R. C., and Bear, M. F. (2004). LTP and LTD: an embarrassment of riches. Neuron 44, 5-21.
39. Malinow, R., and Malenka, R. C. (2002). AMPA receptor trafficking and synaptic plasticity. Annu. Rev. Neurosci. 25, 103-126.
40. Marcello, E., Epis, R., and Di Luca, M. (2008). Amyloid flirting with synaptic failure: towards a comprehensive view of Alzheimer's disease pathogenesis. Eur. J. Pharmacol. 585, 109-118.
41. Martin, L. J., Fournier, N. M., Galic, M. A., and Emond, M. H. (2004). Chronic administration of the L-type calcium channel blocker nimodipine can facilitate the acquisition of sequence learning in a radial-arm maze. Behav. Pharmacol. 15, 133-139.
42. Mayer, M. L., Westbrook, G. L., and Guthrie, P. B. (1984). Voltagedependent block by Mg2+ of NMDA responses in spinal cord neurones. Nature 309, 261-263.
43. Medina, A. E. (2010). Vinpocetine as a potent antiinflammatory agent. Proc. Natl. Acad. Sci. U.S.A. 107, 9921-9922.
44. Medina, A. E., and Krahe, T. E. (2008). Neocortical plasticity deficits in fetal alcohol spectrum disorders: lessons from barrel and visual cortex. J. Neurosci. Res. 86, 256-263.
45. Medina, A. E., Krahe, T. E., and Ramoa, A. S. (2006). Restoration of neuronal plasticity by a phosphodiesterase type 1 inhibitor in a model of fetal alcohol exposure. J. Neurosci. 26, 1057-1060.
46. Menniti, F. S., Faraci, W. S., and Schmidt, C. J. (2006). Phosphodiesterases in the CNS: targets for drug development. Nat. Rev. Drug Discov. 5, 660-670.
47. Molnar, P., and Gaal, L. (1992). Effect of different subtypes of cognition enhancers on long-term potentiation in the rat dentate gyrus in vivo. Eur. J. Pharmacol. 215, 17-22.
48. Molnar, P., Gaal, L., and Horvath, C. (1994). The impairment of long-term potentiation in rats with medial septal lesion and its restoration by cognition enhancers. Neurobiology 2, 255-266.
49. Morgante, F., Espay, A. J., Gunraj, C., Lang, A. E., and Chen, R. (2006). Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain 129, 1059-1069.
50. Mower, A. F., Liao, D. S., Nestler, E. J., Neve, R. L., and Ramoa, A. S. (2002). cAMP/Ca2+ response element-binding protein function is essential for ocular dominance plasticity. J. Neurosci. 22, 2237-2245.
51. Nalbantoglu, J., Tirado-Santiago, G., Lahsaini, A., Poirier, J., Goncalves, O., Verge, G., Momoli, F., Welner, S. A., Masicotte, G., Julien, J. P., and Shapiro, M. L. (1997). Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature 387, 457-458.
52. Nicholson, C. D. (1990). Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology (Berl.) 101, 147-159.
53. Nithianantharajah, J., and Hannan, A. J. (2006). Enriched environments, experience-dependent plasticity and disorders of the nervous system. Nat. Rev. Neurosci. 7, 697-709.
54. Nowak, L., Bregestovski, P., Ascher, P., Herbet, A., and Prochiantz, A. (1984). Magnesium gates glutamate-activated channels in mouse central neurons. Nature 307, 462-465.
55. Parsons, W. D., and Neims, A. H. (1981). Prolonged half-life of caffeine in healthy term newborn infants. J. Pediatr. 98, 640-641.
56. Perrier, J. F., Alaburda, A., and Hounsgaard, J. (2002). Spinal plasticity mediated by postsynaptic L-type Ca2+ channels. Brain Res. Brain Res. Rev. 40, 223-229.
57. Person, A., and Raman, I. M. (2010). Deactivation of L-type Ca current by inhibition controls LTP at excitatory synapses in the cerebellar nuclei. Neuron 66, 550-559.
58. Pintchovski, S. A., Peebles, C. L., Kim, H. J., Verdin, E., and Finkbeiner, S. (2009). The serum response factor and a putative novel transcription factor regulate expression of the immediateearly gene Arc/Arg3.1 in neurons. J. Neurosci. 29, 1525-1537.
59. Puzzo, D., Staniszewski, A., Xiandeng, S., Privitera, L., Leznik, E., Liu, S., Zhang, H., Feng, Y., Palmeri, A., Landry, D. W., and Arancio, O. (2009). Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-load in an Alzheimer's disease mouse model. J. Neurosci. 29, 8075-8086.
60. Raff, M. C., Barres, B. E., Burne, J. F., Coles, H. S., Ishizaki, Y., and Jacobson, M. D. (1993). Programmed cell death and the control of cell survival: lessons from the nervous system. Science 262, 695-700. Ramanan, N., Shen, Y., Sarsfield, S., Lemberger, T., Schutz, G., Linden, D. J., and Ginty, D. D. (2005). SRF mediates activity-induced gene expression and synaptic plasticity but not neuronal viability. Nat. Neurosci. 8, 759-767.
61. Rose, G. M., Hopper, A., De Vivo, M., and Tehim, A. (2005). Phosphodiesterase inhibitors for cognitive enhancement. Curr. Pharm. Des. 11, 3329-3334.
62. Sancesario, G., Giorgi, M., D'Angelo, V., Modica, A., Martorana, A., Morello, M., Bengtson, C. P., and Bernardi, G. (2004). Down-regulation of nitrergic transmission in the rat striatum after chronic nigrostriatal deafferentation. Eur. J. Neurosci. 20, 989-1000.
63. Schachtelle, C., Wagner, B., and Marme, D. (1987). Stereoselective inhibition of calmodulin-dependent cAMP phosphodiesterase from bovine heart by (+)- and (-)-nimodipine. Naunyn Schmiedebergs Arch. Pharmacol. 335, 340-343.
64. Schmidt, B., Roberts, R. S., Davis, P., Doyle, L. W., Barrington, K. J., Ohlsson, A., Solimano, A., and Tin, W. (2007). Long-term effects of caffeine therapy for apnea of prematurity. N. Engl. J. Med. 357, 1893-1902.
65. Serulle, Y., Zhang, S., Ninan, I., Puzzo, D., McCarthy, M., Khatri, L., Arancio, O., and Ziff, E. B. (2007). A GluR1-cGKII interaction regulates AMPA receptor trafficking. Neuron 56, 670-688. Siarey, R. J., Stoll, J., Rapoport, S. I., and Galdzicki, Z. (1997). Altered longterm potentiation in the young and old Ts65Dn mouse, a model for Down syndrome. Neuropharmacology 36, 1549-1554.
66. Siarey, R. J., Villar, A. J., Epstein, C. J., and Galdzicki, Z. (2005). Abnormal synaptic plasticity in the Ts1Cje segmental trisomy 16 mouse model of Down syndrome. Neuropharmacology 49, 122-128.
67. Silva, A. J., Kogan, J. H., Frankland, P. W., and Kida, S. (1998). CREB and memory. Annu. Rev. Neurosci. 21, 127-148.
68. Stevenson, D. K. (2007). On the caffeination of prematurity. N. Engl. J. Med. 357, 1967-1968.
69. St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J. M., Rhee, J., Jager, S., Handschin, C., Zheng, K., Lin, J., Yang, W., Simon, D. K., Bachoo, R., and Spiegelman, B. M. (2006). Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127, 397-408.
70. Striessnig, J., Koschak, A., Sinnegger-Brauns, M. J., Hetzenauer, A., Nguyen, N. K., Busquet, P., Pelster, G., and Singewald, N. (2006). Role of voltagegated L-type Ca2+ channel isoforms for brain function. Biochem. Soc. Trans. 34, 903-909.
71. Suzuki, S., Zhou, H., Neumaier, J. F., and Pham, T. A. (2007). Opposing functions of CREB and MKK1 synergistically regulate the geometry of dendritic spines in visual cortex. J. Comp. Neurol. 503, 605-617.
72. Szatmari, S. Z., and Whitehouse, P. J. (2003). Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst. Rev. 1, CD003119.
73. Tyan, S. W., Tsai, M. C., Lin, C. L., Ma, Y. L., and Lee, E. H. (2008). Serumand glucocorticoid-inducible kinase 1 enhances zif268 expression through the mediation of SRF and CREB1 associated with spatial memory formation. J. Neurochem. 105, 820-832.
74. Vereczkey, L. (1985). Pharmacokinetics and metabolism of vincamine and related compounds. Eur. J. Drug Metab. Pharmacokinet. 10, 89-103.
75. Vitolo, O. V., Sant'Angelo, A., Costanzo, V., Battaglia, F., Arancio, O., and Shelanski, M. (2002). Amyloid betapeptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibilty by drugs that enhance cAMP signaling. Proc. Natl. Acad. Sci. U.S.A. 99, 13217-13221.
76. Volakakis, N., Kadkhodaei, B., Joodmardi, E., Wallis, K., Panman, L., Silvaggi, J., Spiegelman, B. M., and Perlmann, T. (2010). NR4A orphan nuclear receptors as mediators of CREB-dependent neuroprotection. Proc. Natl. Acad. Sci. U.S.A. 107, 12317-12322.
77. Yashiro, K., Riday, T. T., Condon, K. H., Roberts, A. C., Bernardo, D. R., Prakash, R., Weinberg, R. J., Ehlers, M. D., and Philpot, B. D. (2009). Ube3a is required for experience-dependent maturation of the neocortex. Nat. Neurosci. 12, 777-783.
78. Ziburkus, J., Dilger, E. K., Lo, F. S., and Guido, W. (2009). LTD and LTP at the developing retinogeniculate synapse. J. Neurophysiol. 102, 3082-3090.